Wed. Dec. 23, 2020 Results of NIH-Sponsored ACTIV-3 Trial Published Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published in the New England Journal of Medicine. The antibody did not provide clinical benefit compared to placebo. The trial, which had been halted to new enrollment in late October following a recommendation by the independent Data and Safety Monitoring Board (DSMB), is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. Although LY-CoV555 did not perform better than placebo in the hospitalized COVID-19 patients studied in this trial, this same investigational monoclonal antibody was granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration in November. The EUA authorized use of LY-CoV555 in non-hospitalized adolescents and adults with mild to moderate COVID-19 symptoms who are at elevated risk of progressing to severe COVID-19 disease. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107